ABT257
Anti-Pro-Collagen Type I, A1/COL1A1
from rabbit, purified by affinity chromatography
Synonym(s):
Pro-collagen alpha-1(I) chain, Pro-Alpha-1 type I collagen
Sign Into View Organizational & Contract Pricing
All Photos(3)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
rabbit
Quality Level
antibody form
affinity isolated antibody
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
mouse, human
technique(s)
flow cytometry: suitable
immunohistochemistry: suitable
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... COL1A1(1277)
General description
Collagen alpha-1(I) chain (UniProt P02452; also known as Alpha-1 type I collagen) is encoded by the COL1A1 gene (Gene ID 1277) in human. Collagen is the major component of the extracellular matrix (ECM) and form the fibrils of tendons, ligaments, and bones. Type I collagen consists of two alpha I chains and one alpha 2 chain. Alpha-1 type I collagen is initially produced as an 1464-amino acid prepro-form with a signal peptide sequence (a.a. 1-22) and two propeptide sequences (a.a. 23-161 and a.a. 1219 –1464), the removal of which yields the mature alpha-1(I) chain. The mature alpha-1(I) chain is composed mostly of a large triple-helical region (a.a. 179-1192) sandwiched between two nonhelical segments known as the N-terminal telopeptide (a.a. 162-178; numbering based on the prepro-form) and the C-terminal telopeptide (a.a. 1193-1218; numbering based on the prepro-form). Collagen can be extracted from tissue via either enzymatic or non-enzymatic means. Collagen extracted using the proteolytic enzyme pepsin corresponds to the large triple-helical region, referred to as atelocollagen because both the N- and C-terminal telopeptides have been cleaved off by pepsin. On the other hand, collagen preparations obtained with non-enzymatic means (e.g. by acid extraction) have the intact telopeptides at both ends.
Specificity
Cat. No. ABT257 Anti-Pro-Collagen Type I, A1/COL1A1 was raised against a sequence derived from the C-terminal propeptide (not the N-terminal propeptide) region. This polyclonal antibody will detect prepro- and pro-, but not mature collagen alpha-1(I) chain.
Predicted to react with a broad range of species based on high sequence homology, including mammalian, avian, fish, and amphibian species.
Immunogen
Epitope: C-terminal propeptide region
Linear peptide corresponding to sequence derived from human Pro-Collagen Type I, A1/COL1A1 C-terminal propeptide region.
Application
Anti-Pro-Collagen Type I Antibody is an antibody against Pro-Collagen Type I for use in Western Blotting, Flow Cytometry, Immunohistochemistry.
Research Category
Cell Structure
Cell Structure
Research Sub Category
Adhesion (CAMs)
Adhesion (CAMs)
Western Blotting Analysis: A representative lot detected Pro-Collagen Type I, A1/COL1A1 in mouse lung and skin tissue lysate.
Flow Cytometry Analysis: A representative lot detected Pro-Collagen Type I, A1/COL1A1 in mouse lung tissue.
Immunohistochemistry Analysis: A representative lot detected Pro-Collagen Type I, A1/COL1A1 in mouse lung tissue.
Flow Cytometry Analysis: A representative lot detected Pro-Collagen Type I, A1/COL1A1 in mouse lung tissue.
Immunohistochemistry Analysis: A representative lot detected Pro-Collagen Type I, A1/COL1A1 in mouse lung tissue.
Quality
Evaluated by Western Blotting in mouse skin tissue lysate.
Western Blotting Analysis: A 1:500 dilution of this antibody detected Pro-Collagen Type I, A1/COL1A1 in 10 µg of mouse skin tissue lysate.
Western Blotting Analysis: A 1:500 dilution of this antibody detected Pro-Collagen Type I, A1/COL1A1 in 10 µg of mouse skin tissue lysate.
Target description
~140 kDa observed
Physical form
Affinity purified
Purified rabbit polyclonal in buffer containing PBS with 0.05% sodium azide.
Storage and Stability
Stable for 1 year at 2-8°C from date of receipt.
Other Notes
Concentration: Please refer to lot specific datasheet.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Timothy Catchpole et al.
PloS one, 15(2), e0229504-e0229504 (2020-02-28)
A subset of neovascular age-related macular degeneration (nvAMD) subjects appears to be refractory to the effects of anti-VEGF treatment and require frequent intravitreal injections. The vascular phenotype of the choroidal neovascular (CNV) lesions may contribute to the resistance. Animal studies
Yu-Chun Chang et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 35(10), e21849-e21849 (2021-09-03)
Macrophages are a critical driver of neovessel formation in tissue-engineered vascular grafts (TEVGs), but also contribute to graft stenosis, a leading clinical trial complication. Macrophage depletion via liposomal delivery of clodronate, a first-generation bisphosphonate, mitigates stenosis, but simultaneously leads to
Maria Giovanna Parisi et al.
International journal of molecular sciences, 22(11) (2021-06-03)
Given the anatomical simplicity and the extraordinary ability to regenerate missing parts of the body, Cnidaria represent an excellent model for the study of the mechanisms regulating regenerative processes. They possess the mesoglea, an amorphous and practically acellular extracellular matrix
W Grant Stevens et al.
Aesthetic surgery journal, 42(1), 56-67 (2021-05-18)
In addition to body contouring, there is anecdotal and clinical evidence of reduced laxity caused by skin tightening after cryolipolysis. However, it has not been established how cryolipolysis triggers dermal changes. The aim of this study was to investigate the
Early natural history of neotissue formation in tissue-engineered vascular grafts in a murine model.
James W Reinhardt et al.
Regenerative medicine, 14(5), 389-408 (2019-06-11)
Aim: To characterize early events in neotissue formation during the first 2 weeks after vascular scaffold implantation. Materials & methods: Biodegradable polymeric scaffolds were implanted as abdominal inferior vena cava interposition grafts in wild-type mice. Results: All scaffolds explanted at
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service